Delivra Health Brands Inc.
EBITDA Turns Positive/Gearing Up for U.S. Product Launch
Published: 10/27/2023
Author: Sid Rajeev, B.Tech, CFA, MBA
Sector: Healthcare | Industry: Drug Manufacturers-Specialty & Generic
| Metrics | Value |
|---|---|
| Current Price | US $0.02 |
| Fair Value | US $0.07 |
| Risk | 3 |
| 52 Week Range | US $0.010-0.035 |
| Shares O/S (M) | 253 |
| Market Cap. (M) | US $4 |
| Current Yield (%) | n/a |
| P/E (forward) | n/a |
| P/B | 1.1 |
Already a subscriber?
Want to know the fair value of the stock?
Subscribe for free to get exclusive insights and data.
Report Highlights
Highlights
In FY2023 (ended June 2023), revenue increased 20% YoY, beating our estimate by 10%. Gross margins improved 11 ppt to 53%, in line with our estimate. EPS improved YoY (from -$0.03 to -$0.001), and was in line with our estimate as well.
DHB sells sleep aid products through its Dream Water brand, and pain relief products through its LivRelief brand. The company’s target markets are large. Rising awareness of the importance of sleep for both physical and mental health is the primary demand driver of sleep aid products.
In FY2023, 68% of sales came from the U.S., and the Middle East, and 32% from Canada. DHB’s products are available in over 30k+ stores including established ret
